IL-12 and CTLA-4 Antibody Combination for Glioblastoma Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glioblastoma multiforme, the most aggressive malignant primary brain tumor, are ineffective due to the tumor's invasive growth pattern and resistance to conventional therapies, and systemic administration of IL-12 is hindered by adverse events at effective doses.
Innovation Solution
Administering a recombinant IL-12 polypeptide with a human immunoglobulin G crystallisable fragment and a non-agonist CTLA-4 antibody, either locally into the tumor or systemically, to enhance immune response and inhibit tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL-12 is administered systemically at effective doses, then tumor-suppressive properties are achieved, but serious adverse events occur including fatalities
Solution Approach 1:
The patent applies local quality by administering IL-12 directly into the tumor tissue rather than systemically. This localized delivery ensures high concentration of IL-12 at the tumor site where it is needed for anti-tumor activity, while minimizing exposure to healthy tissues and reducing the risk of systemic adverse events. The injection method targets the tumor mass specifically, creating a localized therapeutic effect.
Solution Approach 2:
The patent uses an intermediary approach by combining IL-12 with anti-CTLA-4 antibodies. The anti-CTLA-4 antibody acts as a mediator that blocks the inhibitory CTLA-4 pathway, enhancing the immune system's response to IL-12. This combination allows for lower doses of IL-12 to be effective, thereby reducing adverse events while maintaining tumor-suppressive properties. The anti-CTLA-4 antibody intermediates the immune activation process.
2Ease of manufacture
If conventional treatments are used for glioblastoma, then standard therapy is applied, but the tumor's invasive growth pattern and resistance make treatments ineffective
Solution Approach 1:
The patent applies parameter changes by fundamentally altering the treatment approach from conventional chemotherapy and radiation to immunotherapy with IL-12 and anti-CTLA-4 antibodies. This changes the mechanism of action from direct cytotoxic effects to immune-mediated tumor destruction. The combination therapy parameters (dose, schedule, route of administration) are optimized to overcome tumor resistance and invasive growth patterns that make conventional treatments ineffective.
Solution Approach 2:
The patent uses a composite therapeutic approach by combining two different immunomodulatory agents: IL-12 (a cytokine that activates immune cells) and anti-CTLA-4 antibodies (that block inhibitory immune checkpoints). This composite therapy creates synergistic effects where IL-12 stimulates immune cell activation and proliferation, while anti-CTLA-4 prevents immune suppression, together overcoming tumor resistance and enhancing treatment effectiveness against invasive glioblastoma.
3Quantity of substance
If IL-12 is administered alone, then immune stimulation occurs, but immunosuppressive mechanisms limit tumor eradication
Solution Approach 1:
The patent merges two immunotherapeutic mechanisms by combining IL-12 administration with anti-CTLA-4 antibody treatment. IL-12 stimulates immune cell activation, proliferation, and cytotoxic activity against tumor cells. The anti-CTLA-4 antibody merges with this effect by blocking the CTLA-4 inhibitory pathway, preventing immune suppression. Together, these combined therapies overcome the immunosuppressive tumor microenvironment and achieve more complete tumor eradication than either therapy alone.
Solution Approach 2:
The patent implements a feedback mechanism where anti-CTLA-4 antibodies counteract the immunosuppressive feedback signals that tumors generate. Tumors typically activate CTLA-4-mediated inhibitory pathways to suppress immune responses. By blocking CTLA-4, the therapy interrupts this negative feedback loop, allowing sustained immune activation and cytotoxic activity against tumor cells, thereby improving complete tumor eradication.
Data Source
AI summary
The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.